Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.
暂无分享,去创建一个
Jeffrey J. Gray | Jeffrey J Gray | Sidhartha Chaudhury | J. J. Gray | S. Chaudhury | Sidhartha Chaudhury
[1] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[2] Sami Mahrus,et al. Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease , 2002, Journal of Virology.
[3] David Baker,et al. Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.
[4] C. Schiffer,et al. Substrate specificity in HIV‐1 protease by a biased sequence search method , 2006, Proteins.
[5] Celia A Schiffer,et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. , 2005, Journal of medicinal chemistry.
[6] Roland L. Dunbrack,et al. Bayesian statistical analysis of protein side‐chain rotamer preferences , 1997, Protein science : a publication of the Protein Society.
[7] Hong Cao,et al. Design of Mutation‐resistant HIV Protease Inhibitors with the Substrate Envelope Hypothesis , 2007, Chemical biology & drug design.
[8] Jan Komorowski,et al. Computational proteomics analysis of HIV‐1 protease interactome , 2007, Proteins.
[9] Zachary Q. Beck,et al. Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases , 2001, Journal of Virology.
[10] V. Trouplin,et al. Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.
[11] Bryan Chan,et al. Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..
[12] Hong Cao,et al. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. , 2008, Journal of the American Chemical Society.
[13] Celia A. Schiffer,et al. Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-p1 Cleavage Site with a V82A Drug-Resistant Mutation in Viral Protease , 2004, Journal of Virology.
[14] D B Evans,et al. Human immunodeficiency virus type‐1 reverse transcriptase and ribonuclease h as substrates of the viral protease , 1993, Protein science : a publication of the Protein Society.
[15] A. Israël,et al. Processing of the precursor of NF-κB by the HIV-1 protease during acute infection , 1991, Nature.
[16] D. Baker,et al. A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Karplus,et al. Effective energy function for proteins in solution , 1999, Proteins.
[18] Arthur J. Olson,et al. Structural Basis for Distinctions between Substrate and Inhibitor Specificities for Feline Immunodeficiency Virus and Human Immunodeficiency Virus Proteases , 2003, Journal of Virology.
[19] M. Hatada,et al. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.
[20] Turkan Haliloglu,et al. Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease. , 2003, Biophysical journal.
[21] Maureen M Goodenow,et al. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. , 2008, Virology.
[22] A. Tomasselli,et al. Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. , 1992, The Journal of biological chemistry.
[23] Tanja Kortemme,et al. Design of Multi-Specificity in Protein Interfaces , 2007, PLoS Comput. Biol..
[24] T. Copeland,et al. Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.
[25] David Baker,et al. Protein-protein docking with backbone flexibility. , 2007, Journal of molecular biology.
[26] J. Tözsér,et al. Amino Acid Preferences for a Critical Substrate Binding Subsite of Retroviral Proteases in Type 1 Cleavage Sites , 2005, Journal of Virology.
[27] R E Cachau,et al. Inhibition and catalytic mechanism of HIV-1 aspartic protease. , 1996, Journal of molecular biology.
[28] D. Lamarre,et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.
[29] C. Schiffer,et al. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. , 2000, Journal of molecular biology.
[30] M. Oswald,et al. Fibronectin is a non‐viral substrate for the HIV proteinase , 1991, FEBS letters.
[31] I. Weber,et al. Amino Acid Preferences of Retroviral Proteases for Amino-Terminal Positions in a Type 1 Cleavage Site , 2008, Journal of Virology.
[32] Celia A Schiffer,et al. Combating susceptibility to drug resistance: lessons from HIV-1 protease. , 2004, Chemistry & biology.
[33] O. Schueler‐Furman,et al. Improved side‐chain modeling for protein–protein docking , 2005, Protein science : a publication of the Protein Society.
[34] C. Debouck,et al. Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease. , 1992, Biochemistry.
[35] Peteris Prusis,et al. A Look Inside HIV Resistance through Retroviral Protease Interaction Maps , 2007, PLoS Comput. Biol..
[36] Arthur J. Olson,et al. Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease , 2000, Journal of Virology.
[37] J. Falloon,et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.
[38] E. Wimmer,et al. Proteolytic processing of polyproteins in the replication of RNA viruses. , 1989, Biochemistry.
[39] Jeffrey J. Gray,et al. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. , 2003, Journal of molecular biology.
[40] K. Chou. Prediction of human immunodeficiency virus protease cleavage sites in proteins. , 1996, Analytical biochemistry.
[41] J. Martinez-Picado,et al. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. , 2000, Virology.
[42] Irene T Weber,et al. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV‐1 protease mutants with substrate analogs , 2005, The FEBS journal.
[43] B. Tidor,et al. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV‐1 protease , 2008, Proteins.
[44] B. Kuhlman,et al. Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. , 2007, Journal of molecular biology.
[45] Yiying Zhang,et al. Specificity rule discovery in HIV-1 protease cleavage site analysis , 2008, Comput. Biol. Chem..
[46] Thorsteinn S. Rögnvaldsson,et al. Comprehensive Bioinformatic Analysis of the Specificity of Human Immunodeficiency Virus Type 1 Protease , 2005, Journal of Virology.
[47] N. Gautham,et al. Exploring conformational space using a mean field technique with MOLS sampling , 2007, Journal of Biosciences.
[48] P. Kollman,et al. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[49] Michael K Gilson,et al. Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease , 2007, Proteins.
[50] C. Schiffer,et al. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. , 2002, Structure.
[51] Jeffrey J. Gray,et al. Conformer selection and induced fit in flexible backbone protein-protein docking using computational and NMR ensembles. , 2008, Journal of molecular biology.
[52] David Baker,et al. Recapitulation and design of protein binding peptide structures and sequences. , 2006, Journal of molecular biology.
[53] S Foundling,et al. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. , 1995, Biochemistry.
[54] S. Wodak,et al. Assessment of CAPRI predictions in rounds 3–5 shows progress in docking procedures , 2005, Proteins.
[55] C. Debouck,et al. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[56] R. Huber,et al. Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .
[57] A Wlodawer,et al. Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.
[58] D. Baker,et al. Native protein sequences are close to optimal for their structures. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[59] Nikolay V. Dokholyan,et al. Identification and Rational Redesign of Peptide Ligands to CRIP1, A Novel Biomarker for Cancers , 2008, PLoS Comput. Biol..
[60] Garrett M Morris,et al. Defining HIV-1 protease substrate selectivity. , 2002, Current drug targets. Infectious disorders.